Comprehensive
understanding and unprecedented access tthe personalized medicine partnering
deals and agreements entered intby the worlds leading healthcare companies.
The Personalized Medicine Partnering Terms and
Agreements report provides comprehensive understanding and unprecedented
access tthe personalized medicine partnering deals and agreements entered intby
the worlds leading healthcare companies.
The
report provides a detailed understanding and analysis of how and why companies
enter personalized medicine partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an
option right tlicense the licensors personalized medicine technology. These
deals tend tbe multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding
the flexibility of a prospective partner’s negotiated deals terms provides
critical insight intthe negotiation process in terms of what you can expect
tachieve during the negotiation of terms. Whilst many smaller companies will be
seeking details of the payments clauses, the devil is in the detail in terms of
how payments are triggered – contract documents provide this insight where
press releases dnot.
This
report contains over 1000 links tonline copies of actual personalized medicine
deals and contract documents as submitted tthe Securities Exchange Commission
by companies and their partners. Contract documents provide the answers
tnumerous questions about a prospective partner’s flexibility on a wide range
of important issues, many of which will have a significant impact on each
party’s ability tderive value from the deal.
The
initial chapters of this report provide an orientation of personalized medicine
dealmaking and business activities.
Chapter
1 provides an introduction tthe report, whilst chapter 2 provides an overview of the trends in personalized
medicine dealmaking since 2009, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3
provides a review of the leading biomarker deals since 2009. Deals are listed
by headline value, signed by big pharma and most active of all biopharma companies.
Where the deal has an agreement contract published at the SEC a link provides
online access tthe contract.
Chapter 4
provides a review of the leading companion diagnostic deals since 2009. Deals
are listed by headline value, sig ned by bigpharma and most active of all
biopharma companies. Where the deal has an agreement contract published at the
SEC a link provides online access tthe contract.
Chapter 5
provides a review of the leading pharmacogenomics deals since 2009. Deals are
listed by headline value. Where the deal has an agreement contract published at
the SEC a link provides online access tthe contract.
Chapter 6
provides a comprehensive listing of the top 50 big pharma companies with a
brief summary followed by a comprehensive listing of personalized medicine
deals including biomarker, companion diagnostic, pharmacogenomics, as well as
contract documents available in the public domain. Where available, each deal
title links via Weblink tan online version of the actual contract document,
providing easy access teach contract document on demand.
Chapter 7
provides a comprehensive and detailed review of biomarker partnering deals
signed and announced since 2009, where a contract document is available in the
public domain. The chapter is organized by stage of development at signing,
deal type (collaborative R&D, co-promotion, licensing etc), and specific
therapy focus. Each deal title links via Weblink tan online version of the deal
record and where available, the contract document, providing easy access teach
contract document on demand.
Chapter 8
provides a comprehensive and detailed review of companion diagnostics
partnering deals signed and announced since 2009, where a contract document is
available in the public domain. The chapter is organized by stage of
development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and specific therapy focus. Each deal title links via Weblink
tan online version of the deal record and where available, the contract
document, providing easy access teach contract document on demand.
Chapter 9
provides a comprehensive and detailed review of pharmacogenomics partnering
deals signed and announced since 2009, where a contract document is available
in the public domain. The chapter is organized by stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc), and
specific therapy focus. Each deal title links via Weblink tan online version of
the deal record and where available, the contract document, providing easy
access teach contract document on demand.
Chapter 10
provides a comprehensive and detailed review of personalized medicine
partnering deals signed and announced since January 2009. The chapter is
organized by specific personalized medicine, biomarkers, companion diagnostics
and pharmacogenomics technology type in focus. Each deal title links via
Weblink tan online version of the deal record and where available, the contract
document, providing easy access teach contract document on demand.
In
addition, a comprehensive appendix is provided organized by personalized
medicine partnering company A-Z , deal type, and therapy type. Each deal title
links via Weblink tan online version of the deal record and where available,
the contract document, providing easy access teach contract document on demand.
Report scope
Personalized
Medicine Partnering Terms and Agreements is intended tprovide the reader with
an in-depth understanding and access tpersonalized medicine trends and
structure of deals entered intby leading companies worldwide.
Personalized Medicine Partnering Terms
and Agreements includes:
- Trends in personalized medicine dealmaking in the biopharma industry since 2009
- Analysis of personalized medicine deal structure
- Access theadline, upfront, milestone and royalty data and contract documents
- Case studies of real-life personalized medicine deals
- Access tover 1000 personalized medicine deal announcements
- The leading personalized medicine deals by value since 2009
- Most active personalized medicine dealmakers since 2007
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each
deal title links via Weblink tan online version of the deal record and where
available, the contract document, providing easy access teach contract document
on demand.
The Personalized Medicine Partnering
Terms and Agreements report provides comprehensive access tavailable deals and
contract documents for over 1000 personalized medicine deals. Analyzing actual
contract agreements allows assessment of the following:
- What are the precise personalized medicine rights granted or optioned?
- What is actually granted by the agreement tthe partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Whis responsible for commercialization?
- Whis responsible for development, supply, and manufacture? How is confidentiality and publication managed?
- How are disputes tbe resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear tdiffer from partner tpartner or deal type tdeal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Personalized Medicine Partnering Terms
and Agreements provides the reader with the following key benefits:
- In-depth understanding of personalized medicine deal trends since 2009
- Access theadline, upfront, milestone and royalty data
- Analysis of the structure of personalized medicine agreements with numerous real life case studies
- Comprehensive access tover 1000 actual personalized medicine deals entered intby the world’s biopharma companies
- Detailed access tactual personalized medicine contracts enter intby the leading fifty bigpharma companies
- Insight intthe terms included in a personalized medicine agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence tassess suitability of your proposed deal terms for partner companies
Spanning
over 1289 pages, “Personalized Medicine
Partnering Terms and Agreements” report covering the Trends in personalized
medicine dealmaking, Leading biomarker deals, Leading companion diagnostic
deals, Leading pharmacogenomics deals, Big pharma personalized medicine deals,
Biomarker contracts dealmaking directory, Companion diagnostic contracts dealmaking
directory, Pharmacogenomics contracts dealmaking directory, Personalized
Medicine dealmaking directory by specific technology type, Personalized
medicine partnering resource center.
For
more information see - http://mrr.cm/ZQc
Find all Pharma and Healthcare Reports
at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.